Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...
The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.
To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...
THOUSAND OAKS, Calif. (Nov. 13, 2020) - Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular (CV) outcomes study (FOURIER) that evaluated the effectiveness ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results